HOME >> BIOLOGY >> NEWS
Study suggests cell-cycle triggers might be cancer drug targets

BOSTON--In an experiment that appears to refute current theory, Dana-Farber Cancer Institute scientists have found that removing three key proteins believed essential to cell division and growth had little impact on normal tissue development of a mouse embryo. These same proteins, when overly active, have been linked to cancer cell proliferation.

With one significant exception, the absence of proteins called cyclin D1, D2, and D3 seemed to have no deleterious effect on development of the tissues and organs of laboratory mouse embryos. "D-type cyclins" are molecules that sense growth signals from the cell's environment and, when appropriate, switch on cell division and growth. But when the system is faulty, the cyclins over-respond to the growth signals and can cause cancerous growth. The discovery that these proteins aren't indispensable lends encouragement to an idea that blocking overactive cyclins could halt the growth of cancer.

In the Aug. 20 issue of Cell, lead author Katarzyna Kozar, MD, and senior author Peter Sicinski, MD, PhD, report on developing the first mouse embryos to date in which all three D-type cyclins were absent or "knocked out." It had been thought that at least one cyclin was required for an embryo to be viable and its tissues to form normally. Yet the "triple-knockout" mouse embryos followed a normal course of cell division and proliferation until as late as 13.5 days, when most tissues and organs are already formed. A typical mouse pregnancy last 18 days.

(In a companion paper in Cell, researchers from Spain report similar findings involving protein kinases called CDK4 and CDK6, which are molecular partners of the D-cyclins. Embryonic mice with both CDK molecules knocked out had normal tissue development as well.)

The unexpectedly viable embryos contradict theory and previous laboratory experiments. The only abnormality in the triple knockout mice was a deficiency of blood-forming cells, causing them to be pa
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
19-Aug-2004


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study narrows search for genes placing men at increased risk for prostate cancer
9. Study links high carbohydrate diet to increased breast cancer risk
10. Study explains spatial orientation differences between sexes
11. Study suggests humans can speed evolution

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2020)... ... January 24, 2020 , ... The Rockies ... capital resources to support early-stage bioscience companies in the state. , ... to find the funding they need to innovate and grow. This program ...
(Date:1/23/2020)... , ... January 23, 2020 , ... ... lifesaving mature red blood cells from stem cells. The red blood cells ... cells, under strictly controlled conditions, for transfusion therapy and replaces the need for ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is ... 100 partner organizations from industry, government, academia and the non-profit sector to ...
Breaking Biology News(10 mins):
(Date:2/11/2020)... ... February 11, 2020 , ... ... pleased to announce the successful results from a long-term follow-up clinical study ... Inspan interspinous fixation device (INSPAN LLC). Unlike extension block design, the Inspan ...
(Date:2/5/2020)... ... February 05, 2020 , ... Rare Disease Day® , held the last ... for Rare Disorders (NORD), to raise awareness amongst the general public and decision-makers about ... Act’s “Behind The Mystery” rare disease series will be shining the light ...
(Date:1/28/2020)... , ... January 28, 2020 ... ... enterprise software solutions for biopharmaceutical R&D, today announced the release of ... Genedata’s focus on supporting the implementation of Multi-Attribute Methods (MAM) for characterizing ...
(Date:1/24/2020)... ... January 24, 2020 , ... The plastic and reconstructive surgeons at ... Jersey epitomize the notion that plastic surgery is much more than just cosmetic surgery ... , Over the last 20 years NJ Top Docs, Dr. Andrew Elkwood, Dr. Michael ...
Breaking Biology Technology:
Cached News: